Cheap supplies of HIV-prevention jab for poorer countries hailed as ‘genuine chance to end’ global epidemic

Lenacapavir was launched in the US at a list price of $28,218 a year. At $40, the twice-yearly injectable drug will be in the same bracket as HIV-prevention pills. Photograph: N Engelbrecht/AP

Cheap supplies of a groundbreaking twice-yearly HIV prevention jab will be available in many poorer countries within two years, funders have promised.

Lenacapavir will cost $40 (£30) a patient a year in 120 low- and middle-income countries from 2027, under two agreements with generic drug manufacturers announced this week.